Table 3.
Univariate Cox analyses of PFS and OS in training and validation cohorts
| Characteristics | Training cohort | Validation cohort | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| PFS | ||||
| Gender (Male vs. Female) | 0.644(0.421–0.985) | 0.042 | 1.017(0.591–1.747) | 0.952 |
| Age (≤ 55 vs. > 55) | 1.754(1.209–2.543) | 0.003 | 1.595(0.938–2.713) | 0.085 |
| Smoke (no vs. yes) | 1.177(0.829–1.672) | 0.362 | 1.003(0.633–1.588) | 0.991 |
| Drink (no vs. yes) | 0.883(0.463–1.685) | 0.707 | 0.934(0.465–1.876) | 0.848 |
| T stage (T1-T2 vs. T3-T4) | 1.825(1.241–2.683) | 0.002 | 1.432(0.897–2.284) | 0.132 |
| N stage (N0-N1 vs. N2-N3) | 1.347(0.945–1.919) | 0.099 | 2.102(1.284–3.440) | 0.003 |
| TNM stage (I-II vs. III-IVa) | 3.355(1.808–6.228) | < 0.001 | 2.456(1.223–4.934) | 0.012 |
| EBV DNA (negative vs. positive) | 2.966(1.987–4.425) | < 0.001 | 2.992(1.758–5.093) | < 0.001 |
| LA (≤ 80.17 vs. > 80.17) | 0.495(0.340–0.719) | < 0.001 | 0.463(0.287–0.747) | 0.002 |
| OS | ||||
| Gender (Male vs. Female) | 0.802(0.440–1.464) | 0.472 | 0.712(0.296–1.716) | 0.449 |
| Age (≤ 55 vs. > 55) | 3.595(2.146–6.021) | < 0.001 | 2.910(1.465–5.779) | 0.002 |
| Smoke (no vs. yes) | 1.206(0.717–2.027) | 0.481 | 1.366(0.704–2.652) | 0.356 |
| Drink (no vs. yes) | 1.200(0.516–2.795) | 0.672 | 1.688(0.737–3.864) | 0.216 |
| T stage (T1-T2 vs. T3-T4) | 2.007(1.115–3.614) | 0.020 | 2.583(1.210–5.512) | 0.014 |
| N stage (N0-N1 vs. N2-N3) | 1.313(0.776–2.222) | 0.311 | 1.655(0.823–3.326) | 0.157 |
| TNM stage (I-II vs. III-IVa) | 8.462(2.065–34.683) | 0.003 | 5.283(1.268–22.022) | 0.022 |
| EBV DNA (negative vs. positive) | 2.358(1.326–4.194) | 0.004 | 2.914(1.324–6.416) | 0.008 |
| LA (≤ 80.17 vs. > 80.17) | 0.324(0.175–0.601) | < 0.001 | 0.219(0.096–0.502) | < 0.001 |
Abbreviations: T Tumor, N Node, TNM Tumor node metastasis, EBV DNA Epstein-Barr virus DNA, HR Hazard ratio, CI Confidence interval, LA Lymphocyte × albumin, PFS Progression-free survival, OS Overall survival